L3VLUP
ProSign in

ARCT · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ARCTLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ARCT
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterARCTLLY
Q3 20205 holders, $129m33 holders, $14.1bn
Q4 20201 holders, $172m29 holders, $17.3bn
Q1 20213 holders, $150m24 holders, $23.0bn
Q2 20211 holders, $98m24 holders, $27.8bn
Q3 20213 holders, $128m31 holders, $29.9bn
Q4 20212 holders, $93m31 holders, $34.7bn
Q1 20223 holders, $77m24 holders, $35.3bn
Q2 20223 holders, $61m33 holders, $42.7bn
Q3 20222 holders, $45m31 holders, $43.4bn
Q4 20222 holders, $47m31 holders, $46.6bn
Q1 20232 holders, $67m33 holders, $44.3bn
Q2 20232 holders, $85m37 holders, $59.6bn
Q3 20233 holders, $76m44 holders, $67.6bn
Q4 20234 holders, $111m45 holders, $73.6bn
Q1 20244 holders, $100m41 holders, $95.3bn
Q2 20243 holders, $73m43 holders, $110bn
Q3 20244 holders, $77m45 holders, $107bn
Q4 20244 holders, $62m46 holders, $93.9bn
Q1 20253 holders, $38m42 holders, $98.4bn
Q2 20253 holders, $43m43 holders, $93.2bn
Q3 20252 holders, $47m39 holders, $86.7bn
Q4 20251 holders, $16m41 holders, $123bn
Q1 20261 holders, $21m39 holders, $106bn
Q2 20261 holders, $19m44 holders, $132bn
ARCT

Arcturus Therapeutics LTD

Holders
3
Reported value
$43m
Buyers
0
Sellers
2

Breadth -2 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
43
Reported value
$93.2bn
Buyers
25
Sellers
22

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 44 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ARCT (1)

ARK Investment Management LLC

Only LLY (41)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Maverick Capital Ltd, and 16 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →